JP2019508063A5 - - Google Patents

Download PDF

Info

Publication number
JP2019508063A5
JP2019508063A5 JP2018559162A JP2018559162A JP2019508063A5 JP 2019508063 A5 JP2019508063 A5 JP 2019508063A5 JP 2018559162 A JP2018559162 A JP 2018559162A JP 2018559162 A JP2018559162 A JP 2018559162A JP 2019508063 A5 JP2019508063 A5 JP 2019508063A5
Authority
JP
Japan
Prior art keywords
mir
cancer
item
recombinant hsv
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018559162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508063A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/015417 external-priority patent/WO2017132552A1/en
Publication of JP2019508063A publication Critical patent/JP2019508063A/ja
Publication of JP2019508063A5 publication Critical patent/JP2019508063A5/ja
Priority to JP2021089151A priority Critical patent/JP7174109B2/ja
Priority to JP2022177413A priority patent/JP2023001236A/ja
Priority to JP2024028567A priority patent/JP2024052881A/ja
Pending legal-status Critical Current

Links

JP2018559162A 2016-01-27 2017-01-27 腫瘍溶解性ウイルスベクター及びその使用 Pending JP2019508063A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021089151A JP7174109B2 (ja) 2016-01-27 2021-05-27 腫瘍溶解性ウイルスベクター及びその使用
JP2022177413A JP2023001236A (ja) 2016-01-27 2022-11-04 腫瘍溶解性ウイルスベクター及びその使用
JP2024028567A JP2024052881A (ja) 2016-01-27 2024-02-28 腫瘍溶解性ウイルスベクター及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662287619P 2016-01-27 2016-01-27
US62/287,619 2016-01-27
PCT/US2017/015417 WO2017132552A1 (en) 2016-01-27 2017-01-27 Oncolytic viral vectors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021089151A Division JP7174109B2 (ja) 2016-01-27 2021-05-27 腫瘍溶解性ウイルスベクター及びその使用

Publications (2)

Publication Number Publication Date
JP2019508063A JP2019508063A (ja) 2019-03-28
JP2019508063A5 true JP2019508063A5 (https=) 2020-06-18

Family

ID=57995301

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018559162A Pending JP2019508063A (ja) 2016-01-27 2017-01-27 腫瘍溶解性ウイルスベクター及びその使用
JP2021089151A Active JP7174109B2 (ja) 2016-01-27 2021-05-27 腫瘍溶解性ウイルスベクター及びその使用
JP2022177413A Withdrawn JP2023001236A (ja) 2016-01-27 2022-11-04 腫瘍溶解性ウイルスベクター及びその使用
JP2024028567A Pending JP2024052881A (ja) 2016-01-27 2024-02-28 腫瘍溶解性ウイルスベクター及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021089151A Active JP7174109B2 (ja) 2016-01-27 2021-05-27 腫瘍溶解性ウイルスベクター及びその使用
JP2022177413A Withdrawn JP2023001236A (ja) 2016-01-27 2022-11-04 腫瘍溶解性ウイルスベクター及びその使用
JP2024028567A Pending JP2024052881A (ja) 2016-01-27 2024-02-28 腫瘍溶解性ウイルスベクター及びその使用

Country Status (18)

Country Link
US (3) US10391132B2 (https=)
EP (2) EP4089166A1 (https=)
JP (4) JP2019508063A (https=)
KR (1) KR20180136435A (https=)
CN (2) CN108884448B (https=)
AR (1) AR107469A1 (https=)
AU (1) AU2017212713B2 (https=)
BR (1) BR112018015390A2 (https=)
CA (1) CA3011933A1 (https=)
DK (1) DK3408382T3 (https=)
ES (1) ES2919953T3 (https=)
IL (2) IL260790B (https=)
MX (1) MX2018009126A (https=)
PT (1) PT3408382T (https=)
RU (2) RU2749050C2 (https=)
SG (2) SG11201806134SA (https=)
TW (1) TWI798168B (https=)
WO (1) WO2017132552A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180136435A (ko) 2016-01-27 2018-12-24 온코루스, 인크. 종양 살상형 바이러스 벡터 및 그의 용도
RS60410B1 (sr) * 2016-04-08 2020-07-31 Krystal Biotech Inc Kompozicije za upotrebu u metodama za tretman rana, poremećaja i bolesti kože
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
US10682425B2 (en) 2016-12-14 2020-06-16 The Regents Of The University Of California Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them
US12121573B2 (en) 2019-07-14 2024-10-22 Tianxin Wang Methods and agents including STING agonist to treat tumor
US12037608B2 (en) * 2017-04-19 2024-07-16 The University Of Tokyo Genetically engineered coxsackievirus, and pharmaceutical composition
JP7165329B2 (ja) 2017-04-28 2022-11-04 東レ株式会社 卵巣腫瘍の検出のためのキット、デバイス及び方法
US11612625B2 (en) 2017-07-26 2023-03-28 Oncorus, Inc. Oncolytic viral vectors and uses thereof
GB201714430D0 (en) * 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
EP3681998A1 (en) 2017-09-11 2020-07-22 IMBA-Institut für Molekulare Biotechnologie GmbH Tumor organoid model
TWI666321B (zh) * 2017-10-23 2019-07-21 大陸商深圳市亦諾微醫藥科技有限公司 用於癌症治療的溶瘤性單純皰疹病毒(oHSV)專性載體及其建構體的建構
CN107723367A (zh) * 2017-10-27 2018-02-23 青岛大学 miRNA‑885‑3p的应用和应用其的产品
CN107674918A (zh) * 2017-11-10 2018-02-09 上海交通大学医学院 has‑mir‑195‑5p作为生物标志物在制备肺癌诊断试剂盒中的应用
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
EP4008333A1 (en) 2018-02-19 2022-06-08 Combined Therapeutics, Inc. Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
CN111867609A (zh) * 2018-03-12 2020-10-30 梅约医学教育与研究基金会 用感染性核酸治疗癌症
WO2019195936A1 (en) * 2018-04-10 2019-10-17 Ilkow Carolina Solange Microrna-based compositions and methods used in disease treatment
EP3781188A4 (en) * 2018-04-13 2022-03-02 2seventy bio, Inc. ADOPTIVE CELL THERAPY
CN108707625B (zh) * 2018-07-03 2021-09-21 云笛生物科技有限公司 mir-124和HER2-shRNA双基因表达盒病毒载体、构建方法、病毒、应用
CN109091492A (zh) * 2018-08-02 2018-12-28 广州安镝声生物医药科技有限公司 lncRNA H19的靶miRNA miR-106b-5p及其应用
CN109091491A (zh) * 2018-08-02 2018-12-28 广州安镝声生物医药科技有限公司 lncRNA H19的靶miRNA miR19a-3p及其应用
CN111117973A (zh) * 2018-10-30 2020-05-08 中国科学院武汉病毒研究所 一种受microRNA调控的重组溶瘤肠道病毒71型及应用
MX2021005448A (es) * 2018-11-13 2021-08-11 Oncorus Inc Polinucleotidos encapsulados y metodos de uso.
TWI690597B (zh) * 2018-11-14 2020-04-11 國立中央大學 泌尿上皮癌的檢測套組及檢測方法
SG11202105422RA (en) * 2018-11-29 2021-06-29 Virogin Biotech Canada Ltd Hsv vector with reduced neurotoxicity
US12398376B2 (en) * 2018-12-06 2025-08-26 National Cancer Center Composition comprising NC886 for improving oncolytic virus activity or production
JP2022516318A (ja) * 2019-01-04 2022-02-25 オンコラス, インコーポレイテッド カプセル化ポリヌクレオチド及び使用方法
CN109762903B (zh) * 2019-01-31 2022-02-01 山东大学齐鲁医院 miR-1246和/或TERF2IP在诊治胶质瘤中的应用
EP3921334A1 (en) 2019-02-08 2021-12-15 Krystal Biotech, Inc. Compositions and methods for delivering cftr polypeptides
WO2020185298A1 (en) * 2019-03-14 2020-09-17 Massachusetts Institute Of Technology Engineered herpes simplex virus-1 (hsv-1) vectors and uses thereof
CN110283794B (zh) * 2019-05-30 2021-04-23 伍泽堂 重组溶瘤病毒以及制备方法、应用和药物
CN112011570B (zh) * 2019-05-31 2023-04-18 北京合生基因科技有限公司 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用
JP2022541197A (ja) * 2019-07-16 2022-09-22 ユニヴェルシテ・コート・ダジュール 腫瘍溶解性ウイルスに対する対象の感受性又は抵抗性を評価する方法、組換えウイルス、その調製、及び使用
US20220267799A1 (en) * 2019-08-05 2022-08-25 Virogin Biotech Canada Ltd Genetically modified enterovirus vectors
CN110468132B (zh) * 2019-08-15 2022-11-25 西南大学 一种sgRNA及转基因表达载体、表达品系、筛选方法
CN110433171B (zh) * 2019-08-20 2022-08-19 中山大学附属第六医院 miRNA-1293在制备抗结直肠肿瘤药物中的应用
CA3157063A1 (en) 2019-10-10 2021-04-15 Oncorus, Inc. Dual viruses and dual oncolytic viruses and methods of treatment
KR102320430B1 (ko) * 2020-01-29 2021-11-03 서울대학교병원 수모세포종에 대한 miR-135b, miR-135a 및 이들의 표적 유전자 AMOTL2의 용도
AU2021256845A1 (en) * 2020-04-14 2022-11-24 Eidgenössische Technische Hochschule Zürich Cell classifier circuits and methods of use thereof
CN113583977B (zh) * 2020-04-30 2025-06-06 杭州康万达医药科技有限公司 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
EP4162951A4 (en) * 2020-06-05 2024-07-10 Shanghai Bao Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMPOSITION OF ENZYMES AND VIRUSES AND ASSOCIATED APPLICATION
US20230242994A1 (en) * 2020-07-10 2023-08-03 Shanghai Miran Biotech Co., Ltd. Fluorescent cross-linked rnase h mutant conjugate, mirna combination and application thereof
MX2023001187A (es) 2020-07-31 2023-04-04 Combined Therapeutics Inc Composiciones y métodos para una vacunación mejorada.
JP2023549218A (ja) * 2020-11-13 2023-11-22 テクニシュ・ウニヴェルシタット・ベルリン MiR-375-およびmiR-1制御コクサッキーウイルスB3は膵毒性および心毒性を持たないが、結腸直腸癌において強い抗腫瘍効率を有する
CN116744951A (zh) * 2020-12-25 2023-09-12 苏州系统医学研究所 一种包含溶瘤病毒的组合物及其在肿瘤治疗中的应用
US20260091069A1 (en) * 2021-03-24 2026-04-02 Virogin Biotech Canada Ltd Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors
BR112023020209A2 (pt) 2021-04-02 2023-12-19 Krystal Biotech Inc Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer
US20250049867A1 (en) * 2021-08-31 2025-02-13 Virogin Biotech Canada Ltd. Engineered oncolytic herpesviruses
CN113637761B (zh) * 2021-10-15 2025-01-24 北京百奥思科生物医学技术有限公司 用于黑色素瘤诊断和治疗的miRNA标志物及其相关产品
WO2023142040A1 (en) * 2022-01-29 2023-08-03 Virogin Biotech Canada Ltd. Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors
CN118634238A (zh) * 2022-06-27 2024-09-13 浙江大学 抗口腔肿瘤药物活性成分及其用途
KR102726438B1 (ko) * 2022-11-29 2024-11-06 주식회사 신렉스 암 세포를 표적으로 하는 복수 개의 miRNA를 발현하도록 유전적 조작된 박테리아 균주
GB2634272B (en) * 2023-10-04 2026-04-22 Averywell Ltd Methods
KR20250051170A (ko) * 2023-10-06 2025-04-17 아주대학교산학협력단 자궁경부암 환자의 조기 사망 예측용 바이오마커
CN119932194A (zh) * 2025-01-23 2025-05-06 上海市第十人民医院 一种用于靶标rna多重分析的共价荧光编码组装体、dna荧光条形码及应用

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244792A (en) 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
JPH0668B2 (ja) 1985-08-30 1994-01-05 財団法人化学及血清療法研究所 単純ヘルペスウイルス遺伝子が組込まれた組換えプラスミド
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5849572A (en) 1990-10-10 1998-12-15 Regents Of The University Of Michigan HSV-1 vector containing a lat promoter
US5849571A (en) 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5879934A (en) 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
GB9415369D0 (en) 1994-07-29 1994-09-21 Lynxvale Ltd Mutant virus
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
GB9700411D0 (en) 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
US6071742A (en) 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
CA2315251A1 (en) 1997-12-17 1999-06-24 Immunex Corporation Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
EP1381280B1 (en) 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
WO2002088327A1 (en) 2001-04-06 2002-11-07 Mount Sinai School Of Medicine Of New York University Methods for viral oncoapoptosis in cancer therapy
DE60232742D1 (de) 2001-10-04 2009-08-06 Immunex Corp Ul16-bindungsprotein 4
KR100900249B1 (ko) 2001-12-07 2009-05-29 포항공과대학교 산학협력단 SIVmac239의 면역원성 플라스미드 및 이들을 함유한AIDS DNA 백신
US8927251B2 (en) 2002-10-07 2015-01-06 The University Of Chicago Targeting of herpes simplex virus to specific receptors
GB0406389D0 (en) 2004-03-22 2004-04-21 Istituto Superiore Di Sanito Recombinant herpes simplex virus and uses therefor
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
KR101295733B1 (ko) 2004-08-20 2013-08-13 비랄리틱스 리미티드 혈액암의 치료방법 및 조성물
AU2005302408B2 (en) 2004-10-28 2012-08-09 The Government of the United States of America as represented by the Department of Veterans Affairs Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
EP1843773A4 (en) 2005-01-17 2008-07-30 Viralytics Ltd METHOD AND COMPOSITION FOR TREATING NEOPLASIA
CA2609142C (en) 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
DK2341149T3 (en) 2005-08-26 2017-02-27 Dupont Nutrition Biosci Aps Use of CRISPR-associated genes (Cas)
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
US20080008686A1 (en) 2006-07-10 2008-01-10 The Brigham And Women's Hospital, Inc. Tetracycline repressor regulated oncolytic viruses
BRPI0716427A2 (pt) 2006-08-11 2014-03-11 Dow Agrosciences Llc Recombinação homóloga mediada por nuclease de apêndice de zinco
US20100111873A1 (en) 2007-02-20 2010-05-06 Russell Stephen J Treating cancer with viral nucleic acid
EP2144632B1 (en) 2007-05-09 2016-11-16 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Synthetic herpes simplex viruses type-1 for treatment of cancers
WO2008143875A1 (en) 2007-05-14 2008-11-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
WO2009111892A1 (en) 2008-03-14 2009-09-17 Ottawa Health Research Institute Microrna mediated oncolytic targeting
NO2700405T3 (https=) 2008-05-29 2018-09-01
WO2009148488A2 (en) 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
GB0810912D0 (en) 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
US9404098B2 (en) 2008-11-06 2016-08-02 University Of Georgia Research Foundation, Inc. Method for cleaving a target RNA using a Cas6 polypeptide
US10662227B2 (en) 2008-11-07 2020-05-26 Dupont Nutrition Biosciences Aps Bifidobacteria CRISPR sequences
JP2012520085A (ja) 2009-03-13 2012-09-06 エーゲン、インコーポレイテッド 生物活性rnaの送達のための組成物及び方法
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
US20130071430A1 (en) 2010-04-09 2013-03-21 The University Of Tokyo Microrna-controlled recombinant vaccinia virus and use thereof
WO2011130749A2 (en) 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
WO2012006181A2 (en) 2010-06-29 2012-01-12 Mount Sinai School Of Medicine Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer
CN103261213A (zh) 2010-10-20 2013-08-21 杜邦营养生物科学有限公司 乳球菌CRISPR-Cas序列
AU2012249390B2 (en) 2011-04-27 2017-03-30 Amyris, Inc. Methods for genomic modification
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
EP2591796A1 (en) 2011-11-10 2013-05-15 Universität Zürich Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy
EP2766035B1 (en) 2011-10-11 2018-03-28 Universität Zürich Prorektorat MNW Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
US20130156808A1 (en) 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US20140363469A1 (en) * 2012-01-19 2014-12-11 Alnylam Pharmaceuticals, Inc. Viral attenuation and vaccine production
US20150166969A1 (en) 2012-02-24 2015-06-18 Fred Hutchinson Cancer Research Center Compositions and methods for the treatment of hemoglobinopathies
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
CN105008918A (zh) 2013-01-04 2015-10-28 西托姆克斯治疗公司 用于检测生物系统中的蛋白酶活性的组合物和方法
MX374532B (es) 2013-06-17 2025-03-06 Broad Inst Inc Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
JP6726824B2 (ja) 2013-07-17 2020-07-22 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション 効率的な遺伝子送達用途のための非毒性hsvベクター及びその製造のための補完細胞
BR112016009465A8 (pt) 2013-10-28 2018-01-30 Univ Pittsburgh Commonwealth Sys Higher Education vetor de hsv oncolítico.
EP3110443A4 (en) 2014-02-27 2017-11-15 Viralytics Limited Combination method for treatment of cancer
RU2696312C2 (ru) 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
CN107530416A (zh) 2015-03-05 2018-01-02 西北大学 非神经侵染的病毒及其用途
US10083137B2 (en) 2015-04-02 2018-09-25 Atmel Corporation Peripheral interface circuit for serial memory
ES2994611T3 (en) 2015-10-19 2025-01-27 Cg Oncology Inc Methods of treating solid or lymphatic tumors by combination therapy
US10612005B2 (en) 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
KR20180136435A (ko) 2016-01-27 2018-12-24 온코루스, 인크. 종양 살상형 바이러스 벡터 및 그의 용도
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
AU2016403583B2 (en) 2016-04-22 2020-05-28 Immvira Co., Limited Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy
ES2972406T3 (es) 2016-08-01 2024-06-12 Virogin Biotech Canada Ltd Vectores del virus oncolítico del herpes simple que expresan moléculas estimuladoras del sistema inmunitario
JP2019527737A (ja) 2016-08-09 2019-10-03 アルケヤール, アルモハナッドALKAYYAL, Almohanad Il12を発現する腫瘍溶解性ラブドウイルス
WO2018049248A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus equipped with bispecific engager molecules
US20190275092A1 (en) 2016-11-01 2019-09-12 Dnatrix, Inc. Combination therapy for treatment of brain cancers
KR20190098215A (ko) 2016-12-21 2019-08-21 멤젠 엘엘씨 무장된 복제-가능 종양 분해 아데노바이러스
US11298420B2 (en) 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
US11612625B2 (en) 2017-07-26 2023-03-28 Oncorus, Inc. Oncolytic viral vectors and uses thereof

Similar Documents

Publication Publication Date Title
JP2019508063A5 (https=)
RU2018130673A (ru) Онколитические вирусные векторы и их применение
JP7652823B2 (ja) 腫瘍溶解性ウイルスベクター及びその使用
ES2544713T3 (es) Métodos basados en microARN y composiciones para el diagnóstico y tratamiento de cánceres sólidos
US9821009B2 (en) Method for modulating microRNA content in living beings and the use thereof
JP2008519606A5 (https=)
JP2015509366A5 (https=)
JP2015504307A5 (https=)
US20250049867A1 (en) Engineered oncolytic herpesviruses
Sheervalilou et al. A review on microRNAs’ function, detection and evaluation methods, expression dysregulation mechanisms and possible applications in clinical phase as diagnostic, prognostic and therapeutic biomarkers of lung cancer patients
Noorali et al. Effec t of Differentially Expressed MicroRNAs 602 and 323-5p on Hepatitis C Viru s Genotype 1b Viral Load in Infected Liver Cells
İmir et al. OVER KANSERİ HÜCRELERİNDE PRİMA-1 Met TEDAVİSİNE YANIT OLARAK DEĞİŞEN miRNA EKSPRESYON ANALİZİ
NZ809978A (en) Bioactive renal cells
NZ809978B2 (en) Bioactive renal cells